

**Oklahoma Health Care Authority  
Drug Utilization Review Board  
(DUR Board)  
Meeting – August 8, 2012 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
  - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. July 11, 2012 DUR Minutes – Vote
  - B. July 12, 2012 DUR Recommendation Memorandum
  - C. Correspondence

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Retrospective Drug Utilization Review for April 2012
  - B. Retrospective Drug Utilization Review Response for February 2012
  - C. Medication Coverage Activity for July 2012
  - D. Pharmacy Help Desk Activity for July 2012

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

- 5. Action Item – Vote to Prior Authorize Qnasl™ and Dymista™ – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

- 6. Action Item – Vote to Prior Authorize Subsys™ – See Appendix D.**
  - A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Keast, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Botulinum Toxin Products – See Appendix E.**
  - A. Cost Comparison
  - B. COP Recommendations

Items to be presented by Dr. Le, Dr. Keast, Chairman

8. **Atypical Antipsychotics Annual Review Follow-Up – See Appendix F.**
  - A. Background
  - B. Efficacy of Abilify®
  - C. Utilization of Abilify®
  - D. Utilization from Inpatient Stabilization
  - E. Conclusions
  - F. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

9. **Annual Review of Synagis® – See Appendix G.**
  - A. Current Authorization Criteria
  - B. Utilization Review
  - C. New Recommendations from AAP
  - D. Referrals to Care Management Services
  - E. RSV Season Recap
  - F. COP Recommendations

Items to be presented by Dr. Keast, Dr. Moore, Dr. Muchmore, Chairman

10. **30 Day notice to Prior Authorize Select Gonadotropin-Releasing Hormone Analogs for Central Precocious Puberty – See Appendix H.**
  - A. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**
12. **Future Business**
  - A. Annual Review of Pradaxa®
  - B. New Fiscal Year Annual Reviews
  - C. New Product Reviews
  - D. Medical Product Reviews
13. **Adjournment**